May 28, 2020 The Lupus Research Alliance is pleased to share that Aurinia Pharmaceuticals Inc submitted a New Drug Application (NDA) to the U.S. FDA for voclosporin as a potential treatment for lupus nephritis with request for a priority review. Lupus nephritis is one of the most common complications of systemic lupus erythematosus, a serious […] READ MORE
NEW YORK, NY, May 28. More than one third of people with lupus experienced significant issues filling their hydroxychloroquine (Plaquenil) prescriptions during the COVID-19 pandemic, according to results of a new survey conducted by the Lupus Research Alliance (LRA). Hydroxychloroquine shortages in March and April coincided with early data broadly reported in the media suggesting […] READ MORE
Since the arrival of the novel coronavirus, lupus and the most prescribed drug used to treat it – hydroxychloroquine – have been thrust into the public spotlight despite the mounting scientific evidence that drug does not appear to improve clinical outcomes in patients with COVID-19. What has been talked about less is what the impact […] READ MORE
May 2020 The entire Board of Trustees and staff of the Lupus Research Alliance (LRA) and Lupus Therapeutics (LT) mourn the passing of Betty Wold Johnson, one of our kindest and most generous benefactors, and beloved mother of Robert Wood “Woody” Johnson, IV, LRA’s Chairman Emeritus and the U.S. Ambassador to the UK. The family […] READ MORE
May 7, 2020 The Lupus Research Alliance held an informative call with the Food and Drug Administration (FDA) in response to the letter spearheaded by the Lupus Research Alliance (LRA) Scientific Advisory Board Chair, Dr. Gary Koretzky, and co-signed by more than a dozen international leaders in Immunology, Rheumatology and Bioethics representing academia, industry and […] READ MORE
May 1, 2020 In the context of the COVID-19 crisis, one disease has taken center stage as the world found out there is much to learn from lupus – from the people who live with this prototypical autoimmune disease as well healthcare providers dedicated to their care and the researchers committed to finding a cure. […] READ MORE
April 23, 2020 The Lupus Research Alliance is pleased to share that Eli Lilly and Company entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID) to test the safety and effectiveness of its drug baricitinib as a potential treatment for hospitalized patients with COVID-19. An oral JAK1/JAK2 inhibitor, baricitinib is […] READ MORE
April 23, 2020 A new study supported by the Lupus Research Alliance discovered a way that harmful immune responses in lupus and lupus nephritis could be stopped while protective immune responses, such as those to infection, are preserved. The findings were published in the prestigious Journal of Immunology and add evidence to the value of […] READ MORE
Updated April 23, 2020 The most commonly prescribed treatment for lupus, hydroxychloroquine (best known as Plaquenil) is not effective for treating COVID-19 according to a new study of 368 hospitalized patients in United States Veteran Administration medical centers. Led by Mr. Joseph Magagnoli, Dr. Siddharth Narendran and Dr. Felipe Pereira at University of South Carolina, […] READ MORE
April 20,2020 The Lupus Research Alliance is proud to share that the COVID-19 Global Rheumatology Alliance, of which the organization is a sponsor, has gathered and published in record time data on 110 people with lupus or another rheumatic disease who also have COVID-19. The paper appeared in the highly prestigious medical journal The Lancet […] READ MORE
April 16, 2020 A recently published study led by Dr. Gregg Dinse provides compelling evidence that proteins found in many people with autoimmune diseases have become more common in Americans over time. Using blood samples taken from 14,211 people representative of the American population, the researchers found that these proteins, also known as anti-nuclear antibodies […] READ MORE
April 16, 2020 Treating people with lupus earlier with belimumab (Benlysta) may work better than as a last option according to a study just published in the well-respected journal Arthritis & Rheumatology Researchers in Italy analyzed data from 466 people with lupus at 24 centers in Italy who were receiving belimumab intravenously. They looked at […] READ MORE
